Enlivex Therapeutics (ENLV) said Wednesday it received authorization from the Israeli Ministry of Health to start a phase 1 clinical trial of Allocetra after injection into the temporomandibular joint in osteoarthritis patients.
The company intends to evaluate the frequency and severity of adverse events, including serious adverse events, as the primary safety endpoint of the trial, which will enroll six participants, it added.
Enlivex said that efficacy endpoints will focus on changes from baseline in temporomandibular joint pain, joint functionality, and other disease parameters for up to 12 months following the injection of Allocetra.
Shares of Enlivex Therapeutics were down 1.6% in recent trading.
Price: 1.23, Change: -0.02, Percent Change: -1.60
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.